Friday, July 24, 2009

Brazil, India & Other Developing Countries Seek Compulsory License to Steal U.S. Patented Climate Change Technologies

http://www.ecoearth.info/shared/reader/welcome.aspx?linkid=132796

http://online.wsj.com/article/SB124760260278140953.html

Fighting Climate Change With Patents


By Tim Wilson


Wall Street Journal Europe


July 15, 2009


GENEVA -- World leaders are talking a lot about climate change, not least in their flashy statement on controlling global temperatures at the recent Group of Eight summit in Italy. One of the smarter ways they can put this determination into effect will be to protect the intellectual property of green innovators from a growing onslaught by developing-world politicians and mistaken activists.



Intellectual property rights are the underappreciated link in the environmentalist chain. By rewarding inventors and entrepreneurs, well-enforced patents provide the right incentives for the innovation that will produce technologies necessary to manage climate change. Yet this fact is getting lost. Access to low carbon technologies has become a central issue in international climate change negotiations as rich countries put more pressure on the poor to cut their emissions. Understandably the poor aren't prepared to do so unless they are given cheap access to technologies. Patents are increasingly viewed as the main obstacle to cheap technology transfer.

Add Image

So a representative of the Brazilian government, Haroldo Machado Filho, this week told a World Intellectual Property Organization conference in Geneva that leaders should consider the possibility of allowing "compulsory licensing" for green technologies.


This would be a new loophole in international intellectual property rules that would allow developing-country governments to break patents "for the public good"; such a loophole already exists for pharmaceuticals.



In a similar vein, Indian Climate Change Minister Shri Ramesh asserted late last month that access to intellectual property for low-carbon technology is a "global public good." This kind of thinking lays the intellectual groundwork for patent violations down the road.


Most worrying, opponents of patents have succeeded in having included in the current negotiating text for a post-Kyoto agreement paragraphs to undermine patents. The final text won't be finalized until at least the December U.N. Copenhagen meeting, but current proposals range from "compulsory licensing" to the "creation of a global technology pool for climate change" that would socialize intellectual property.



These proposals fundamentally misunderstand why low-carbon technology is expensive. A January report by Copenhagen Economics, a consulting firm, found that the high prices are most likely a result of the immaturity of technologies, not patents. New technologies are generally more expensive when there are fewer products competing in the market. As more technologies are innovated the price is likely to drop. Most promising green technologies are so new they simply haven't had time to decline in price yet.


The Copenhagen Economics report also notes that weakening intellectual property for green technologies would be bad for the developing world countries whose governments advocate such measures. A growing number of patents on these technologies are held by developing-country innovators. China is one of the largest owners of solar and fuel-cell technology patents. The balance is still in favor of developed-world innovators, but the gap is narrowing fast. Allowing entrepreneurs in poorer countries to profit from their discoveries will be good both for the environment and for developing-country economies.


Undermining patents won't help access to technologies, but it will stop the next generation of technologies being invented, and with it a long-term solution to achieving the twin goals of developing countries to reduce emissions and alleviate poverty. Rather than breaking patents, policy makers could re-evaluate tariff regimes and other barriers that can add up to 165% to the cost of some imported green technologies, according to a 2007 World Bank study. The best path to a green future is not to break free-market principles, but to return to them.

Mr. Wilson is director of the Institute of Public Affairs in Melbourne, Australia.

-------------------------------------------------------------------------------------------------

http://www.twnside.org.sg/title2/intellectual_property/info.service/2009/twn.ipr.info.090609.htm

No patents on climate-friendly technologies, says South

SUNS #6718


by Sangeeta Shashikant


Third World Network


June 12, 2009



The Group of 77 and China as well as several developing countries in their individual capacity have ma de proposals calling f or climate-friendly technologies to be excluded from patenting.


In their text submitted Wednesday, the G77 and China proposed that "All necessary steps shall be immediately taken in all relevant fora to mandatorily exclude from patenting climate-friendly technologies held by Annex II countries which can be used to adapt to or mitigate climate change". [Annex II of the Convention contains a list of 24 developed countries with financial obligations].



The "no patents" proposal is one of several other ambitious proposals put forward by developing countries to address the intellectual property barrier to the transfer of and access to environmentally-sound technologies for climate mitigation and adaptation (ESTs).



The proposals were submitted on "Enhanced action on development and transfer of technology", one of the five building blocks of the Bali Action Plan (BAP) adopted by Parties tothe UN Framework Convention on Climate Change (UNFCCC) in December 2007. These proposals were added during the discussion of the text of the Chair of the Ad-hoc Working Group on Long-Term Co-operative Action (AWG-LCA) in the informal plenary on 10 June.


The work of the AWG-LCA is to implement the Bali Action Plan in order to enable the full, effective and sustained implementation of the UNFCCC through long-term cooperative action now, up to and beyond 2012.


Developing countries also called for: (i) the adoption of a Declaration on IPRs and Environmentally Sound Technologies in relevant fora; (ii) the use to the full flexibilities contained in the TRIPS Agreement including compulsory licensing to access intellectual property protected technologies; (iii) steps to ensure sharing of publicly funded technologies and related know-how; and (iv) the creation of a "Global Technology Pool for Climate Change" that ensures access to technologies including on royalty free terms.


The call for bold action to deal with IPRs, an obstacle to the transfer of and access to ESTs, follows heated debate that took place last Saturday, largely along North-South lines.



Developed countries, in particular Japan, Canada, Australia, Switzerland and the US insisted on strong IPR regimes, even opposing the use of compulsory licensing, which is allowed under the TRIPS Agreement (See SUNS #6716 dated 10 June 2009). The developed countries also questioned the need for new institutional arrangements, in particular, the technology mechanism that has been proposed by the G77 and China.


On the other hand, developing countries had argued that there was a need for patent exclusion on climate technologies, given the need for a global and systemic response to address the global challenge of climate change, adding that the current TRIPS flexibilities were inadequate.


The Philippines proposed that: "All necessary steps shall be immediately taken in all relevant fora to mandatorily exclude from patenting environmentally sound technologies which can be used to adapt to or mitigate climate change".

The Philippines also proposed that: "Biological resources including microorganisms, plant and animal species and varieties, and parts thereof that are used for adaptation and mitigation of climate change shall not be patented".


Bolivia proposed that Parties should "take all steps necessary in all for a to mandatorily exclude from patenting in developing countries environmentally sound technologies to adapt to or mitigate climate change, including those developed through funding by governments or international agencies" and "to revoke in developing countries all existing patents on essential/urgent environmentally sound technologies to adapt to or mitigate climate change".



It also proposed text that "nothing in any international agreement on intellectual property shall be interpreted or implemented in a manner that limits or prevents any Party from taking any measures to address adaptation or mitigation of climate change, in particular the development and transfer of, and access to technologies".


Other developing countries have also made proposals reflecting a similar sentiment as follows:


"[[LDCs][Countries vulnerable to the adverse effects of climate change] should be exempted from patent protection of climate-related technologies for adaptation and mitigation, as required for capacity building and development needs.


[Genetic resources, including germplasms of plant and animal species and varieties that are essential for adaptation in agriculture, shall not be patented by multinational or any other corporations.]]]"


Aside from the "no patents" proposal, the Chair's text as well as the various submissions of countries during the technology debate also contains other proposals to address the IPR barrier.


Some of the proposals envisage bolder actions to overcome the IPR obstacle, such as "Limited/reduced time for patents on climate friendly technologies".


The Philippines proposed language to improve the Chair's text that supported the use of TRIPS flexibilities as well as to ensure the sharing of publicly-funded technologies and related know-how. It proposed the following:



"Specific measures shall be taken and mechanisms developed to remove existing barriers to development and transfer of technologies from developed to developing country Parties arising from intellectual property rights (IPR) protection, including:



(i) to use to the full flexibilities contained in the Trade Related Aspects of Intellectual Property Rights (TRIPS) including Compulsory licensing to access intellectual property protected technologies;



(ii) take steps to ensure sharing of publicly funded technologies and related know-how including by making the technologies available in the public domain at an affordable price and on terms and conditions that promotes access for developing countries".



The Philippines also proposed the "adoption of a Declaration on IPRs and Environmentally Sound Technologies in relevant fora to inter alia reaffirm the flexibilities in the TRIPS Agreement and enhance the enabling environment for implementing these flexibilities".


The Chair's text had "Compulsory licensing for specific patented technologies" as a specific measure to remove IPR protection barriers to technology development and transfer.



The G77 and China proposed the "creation of a Global Technology Pool for Climate Change' that promotes and ensures access to intellectual property protected technologies and associated know-how to developing countries including on non-exclusive royalty-free terms in order to provide better information service and reduce transaction costs".



The Philippines made a similar proposal in its submission including an additional paragraph that states: "All necessary measures and actions shall be immediately taken to facilitate technology pools that include associated trade secrets and know-how on environmentally sound technologies and enable them to be accessed, including on royalty-free terms for developing countries".


The technology pool proposal is similar to a proposal in Bolivia's submission. The Bolivian proposal also speaks of immediately creating and providing "new and additional financing that is adequate, predictable and sustainable for joint technology excellence centres in developing countries, to enable entities in these countries to do research and development especially on adaptation as well as mitigation technologies" and "to ensure that any technology transfer to developing countries is appropriate for the developing countries concerned in order to enable its effective utilization".


(The immediacy is based on the mandate of the AWG-LCA to enhance implementation of the Convention "now, up to and beyond 2012".)


The Chair's text also contains a proposal for "The Executive Body on Technology", "to establish a committee, an advisory panel, or designate some other body, to proactively address patents and related intellectual property issues to ensure both increased innovation and increased access both for mitigation and adaptation technologies".



It further states that the committee/panel should:



"(a) Actively engage enterprises and institutions in both developed and developing countries; (b) Develop a clear framework for evaluation and determining when intellectual property becomes a barrier to international technology research, development, deployment, diffusion and transfer and provide options for corrective action; ( c) Make recommendation back to the UNFCCC COP or COP/MOP on barriers that may require further actions".



There are also proposals in the Chair's text that mention "Preferential pricing", "Differential pricing between the developed and developing countries", "promoting innovative IPR sharing arrangements for joint development of Environmentally Sound Technologies", and "Promoting Joint technological or patent pools for the development and transfer of technologies to the developing countries at low cost". +

------------------------------------------------------------------------------------------------

http://www.scidev.net/en/climate-change-and-energy/adaptation/opinions/cooperation-not-compulsion-on-clean-tec hnology-tra.html

Cooperation not compulsion on clean technology transfer



by Dalindyebo Shabalala


Science and Development Network


3 June 2009

Compulsory licensing of clean technologies will only be needed if developed countries duck UNFCCC obligations, says Dalindyebo Shabalala.



Developing countries will need 'clean technologies', such as micro-wind energy, if they are to play an active role in combating climate change over the coming decades. The question is how to access these? The answer lies in genuine cooperative technology transfer between the developed and developing world.


Compulsory licensing, where governments allow manufacturers to produce patent-protected goods for domestic use without the patent owner's consent (sometimes with payment),is one option. It has worked well for medicine, though developing nations have had to fight hard to access some key drugs. And some countries, including Thailand, have suffered severe political penalties, such as threats to remove or suspend trade preferences.



Many in the climate change debate argue for new and more flexible compulsory licences for clean technologies, especially given potential demand in developing countries and the short time frame for action.



A last resort?


Individual countries could unilaterally use existing World Trade Organization rules for compulsory licences to access key clean technologies. But that — and any new licensing system — should only be needed if industrialised nations fail to meet their technology transfer and financing commitments under the UN Framework Convention for Climate Change (UNFCCC).


Some proponents of new compulsory licensing for climate-related technologies have misunderstood key differences between the access to medicines debate (under the TRIPS Agreement) and technology transfer, under the UNFCCC.

Whereas TRIPS contains just one relatively weak commitment to technology transfer that only refers to least developing countries, the UNFCCC addresses it extensively, giving clear guidelines, especially on financing, for developed and developing countries.



And there are other factors that compulsory licences may not resolve. For example, for many climate technologies, such as micro-hydroelectric, wind and solar, the major cost may not be the intellectual property (IP), but the actual hardware and maintenance.



More than access to the actual technologies, developing countries need access to the skills, know-how and capital that can help them use, reproduce and adapt clean technologies. Compulsory licences — except those granted for competition reasons — may not transfer this tacit knowledge, which is often protected by trade secrets.



UNFCCC obligations


Under the UNFCCC, industrialised countries are committed to providing and financing technology transfer, regardless of patents. They are obliged to make available funds and mechanisms to ensure access, distribution and uptake of environmentally sound climate-related technologies in developing countries. For example, the [UN] Montreal Protocol — an international treaty to protect the ozone layer — pays for licensing fees at reasonable costs. Countries remain free to exercise compulsory licences when companies refuse to license their products.



The Montreal Protocol — and the UNFCCC — also account for IP market failures, where patented goods or knowledge become unaffordable for most relevant consumers. Under them, developed countries guarantee to transfer technologies, including paying for licences, if the technology in question exists and is unavailable in the national market at an affordable cost.



Unlike compulsory licensing, this commitment represents a cooperative approach. Only if this fails will developing countries, left to their own devices, have to resort to unilateral measures.



Those engaged in the current UNFCCC negotiations are well aware that agreeing a workable mechanism for technology transfer is essential. It is crucial for strategies to successfully combat climate change after 2012 (when the first commitment period of the Kyoto Protocol ends).



Lessons from Montreal


The Montreal Protocol shows technology transfer can be successfully addressed. What is needed is a fully funded financing mechanism that pays the full costs of accessing technologies, especially patent licences and accompanying services. And there must be a fair mechanism for managing intellectual property barriers, such as refusals to license, unreasonably high licensing costs, restrictive licensing practices, and other issues.



Developing countries at the UNFCCC are proposing a Technology Cooperation Mechanism that draws on experiences of the Montreal Protocol. Developed countries, who have not yet proposed any mechanisms themselves, need to acknowledge the success of experiences such as the Montreal Protocol and actively join with developing countries in seeking a cooperative and good faith solution. Only then can developing countries begin to effectively take on the challenge of reducing greenhouse gas emissions and adapting to climate change.



In the meantime, developing countries will continue to use compulsory licensing as a bargaining chip.



But we should all hope that unilateral measures remain nothing more than that. If developing countries have to resort to large-scale compulsory licensing to acquire climate-related technologies, it will signify a fundamental breakdown in the global climate policy regime. Developing countries will have been left on their own to sink or swim in a deluge of someone else's making.



Dalindyebo Shabalala is director of the Intellectual Property and Sustainable Development Project at the Center for International Environmental Law (CIEL). The views expressed in this piece do not necessarily reflect the views of CIEL or its funders.

-------------------------------------------------------------------------------------------------

http://nopr.niscair.res.in/bitstream/123456789/4193/1/JIPR%2014(3)%20241-246.pdf

http://nopr.niscair.res.in/handle/123456789/4193

Diffusion of Climate Friendly Technologies: Can Compulsory Licensing Help?


By Nitya Nanda,


Centre for Global Agreements, Legislation and Trade, Resources and Global Security Division, The Energy and Resources Institute (TERI), India Habitat Centre, New Dehli 110 003


14 Journal of Intellectual Property Rights 241


May 2009


Abstract:


Countries often resort to compulsory licensing to promote diffusion of technologies, particularly when intellectual property rights (IPR) holder is considered to have abused its dominant position. However, use of this instrument is often difficult due to legal, political and operational problems. In this context, this paper reviews global regimes as well as national regimes in major jurisdictions, governing use of compulsory licensing. It also examines functional requirements and market conditions for compulsory licensing to work.


Based on these, it concludes that the global IPR regime under the WTO needs a mechanism similar to that has been developed for pharmaceutical products, and a more flexible regime even in that, as most countries do not have domestic manufacturing capabilities, if compulsory licensing has to work for the diffusion of climate friendly technologies. However, even such a flexible mechanism may not be adequately effective due to highly concentrated market structure of these technologies, particularly in developing countries.

Tuesday, May 12, 2009

Colombia Caves to Health Extremists to Violate the Property and Human Rights of Foreigners

http://www.forbes.com/feeds/prnewswire/2009/05/11/prnewswire200905112122PR_NEWS_USPR_____DC15231.html

Victory! Colombian Government Cuts Price of Abbott's Lifesaving AIDS Drug Kaletra 55%, Says AHF


Forbes.com


May 11, 2009


05.11.09, 9:28 PM ET


Advocates Claim Victory as Government Cuts & Freezes Price at $1,067 USD for Public Institutions and $1,591 USD for Hospitals, Clinics & Private Sector--55% Less than Abbott's Previous Colombian Price. Since January, Colombian, Mexican & US AIDS Advocates Protested Steep Price of Drug in Developing Countries; Compulsory License in Colombia Would Further Cut Price to Less Than $600/Patient/Yearly


MEXICO CITY, May 11 /PRNewswire-USNewswire/ -- Colombian and international AIDS advocates and activists claimed victory today after the government of Colombia announced that it will cut the price of Abbott Laboratories' lifesaving AIDS drug, Kaletra to $1,067 USD for the public sector hospitals and clinics and $1,591 USD for the private sector. Government officials had asked the Chicago-based pharmaceutical giant to voluntarily lower the price; however, the company refused. As a result, Colombia invoked its power to cut and freeze the price of the key AIDS drug. The cut represents a roughly 55% price reduction in Colombia, where Abbott previously charged the private sector approximately $3,500 USD per patient yearly for the drug.


"Colombia's action today to cut the price for Abbott's Kaletra is of major importance, a move that will undoubtedly help save many, many lives by making lifesaving AIDS drug regimens more widely available in the country. We salute the tireless AIDS activists and advocates on the ground who raised awareness through protests and media outreach that helped keep this issue in the forefront. I am not aware of another instance in which the government of a country came in and cut and put a price ceiling on an AIDS drug." said Clint Trout, MPH "However while this is an important victory, we call on the Colombian government to accede to local activists demands to issue a compulsory license for Kaletra, which would allow Colombia to purchase the medication at less than $600 per patient per year and would save many additional lives."


[ILLEGAL EXPROPRIATION OF FOREIGN ASSETS, IN VIOLATION OF THE WTO TRIPS AGREEMENT]


In January of this year, as part of an ongoing multinational campaign to lower drug prices and improve access to lifesaving AIDS treatments globally, AIDS advocates from three countries--Colombia, Mexico and the United States--held simultaneous protests in the three countries. The protests targeted Chicago-based Abbott Laboratories over the pricing of Kaletra, which can be a key component of lifesaving AIDS drug treatment regimens, particularly as part of what are known as 'second-line' treatments and salvage therapy. The advocates vowed to seek compulsory licenses in Mexico if Abbott did not reduce prices for the drug and have officially requested a compulsory license in Colombia. The Colombian Government is expected to rule on the compulsory license this week.



"In our protests in the three countries in January, we pressed Abbott to reduce the price of Kaletra in Colombia and Mexico," said Michael Weinstein, AIDS Healthcare Foundation President. "The lives of people living with--and dying from--HIV/AIDS in Colombia and Mexico are just as important as those of people living with AIDS here in the United States. In March, we claimed partial victory when Abbott cut the price of Kaletra by twenty percent in Mexico. Today's action by the Colombian government helps bring about an end to Abbott's price-gouging policies that shamefully continue to place profits ahead of saving lives. We call on the Colombian government to use these savings to improve treatment and care for persons living with HIV/AIDS in Colombia."



In late March, a coalition of AIDS activists [EXTREMISTS] known as the Coalicion de Activistas por el Acceso Universal spearheaded by AIDS Healthcare Foundation (AHF), which operates four free treatment clinics in Mexico (Puerto Vallarta, Cancun, Tuxtla Gutierrez and Pachuca), declared victory in its campaign to lower drug prices and improve access to lifesaving AIDS treatments in Mexico. As a result of that coalition's prolonged, multinational campaign to raise awareness about the high price charged by Abbott Laboratories Inc. for its key AIDS drug, Kaletra in Mexico, the company cut its price by twenty percent--from $4688.00 pesos MXN per patient per month to $3750.40 MXN. The new lower price was published for the first time in med-March on the website of CENSIDA, Mexico's National Center for the Prevention and Control of HIV/AIDS.



The Colombian [EXTREMIST] organizations: Mesa de Organizaciones con Trabajo en VIH/SIDA, the Red Colombiana de Personas Viviendo con VIH o con SIDA, Mission Salud, and IFARMA requested a compulsory license for Kaletra from the Ministry of Commerce in 2008 and have been leading the push for the compulsory license and lower prices with assistance from AHF and Washington-based Essential Action. The Ministry of Commerce has requested the Ministry of Social Protection to rule whether or not Kaletra is a medication "in the public interest." This ruling is expected this week.



Abbott has long been the target of multinational protests and legal actions over the pricing of its AIDS drugs including Kaletra and Norvir. Over the past several years as many of Abbott's industry peers have significantly lowered the prices of their own lifesaving AIDS medicines on their own volition and in response to worldwide humanitarian need, Abbott has remained steadfast in its refusal to do so, or it has countered advocates' and governments' demands with only modest price reductions.



According to the website, www.aidsmeds.com , "Kaletra, a protease inhibitor (sold under the brand name Aluvia in some parts of the world), is actually two drugs combined into a single capsule: lopinavir and low doses of ritonavir (Norvir), another protease inhibitor manufactured by Abbott Laboratories. This is because ritonavir increases the amount of lopinavir in the blood, thus making it more effective against HIV."



Kaletra in Colombia



-- Colombia is a lower-middle income country with an average income per capita of $2,600 per year.(1) The country has one of the most serious HIV/AIDS problems in the region: 170,000 people living with AIDS and a rapidly rising HIV prevalence (currently 0.7%).(2) An average of 10,000 people each year die from AIDS in the country.(3)



-- Colombia is unable to provide antiretroviral therapy to those who need it. UNAIDS estimates that 33,000 people with AIDS who need ARV therapy now (62% of the total) are not currently accessing it.(4) Colombia's government is spending $70 million each year for AIDS drugs (all national funding).(5)



-- Abbott promotes Colombia as receiving a preferred price of $1,000 per patient per year for lower-middle income countries on its website.(6) However, in reality Abbott charged Colombia $8,400 per patient per year up through mid-2007.(7)(8) Abbott is currently charging $3,500 in Colombia.(9)



-- Abbott uses unorthodox and unethical marketing strategies in Colombia to promote Kaletra. This includes offering classes, dinners, and trips to patients on Kaletra.(10) As a result, Kaletra is the 2nd-most widely prescribed AIDS medicine in Colombia, highly unusual for a 2nd-line medication. Kaletra accounts for 1/3 of Colombia's AIDS drug costs.(11)



-- On April 7, 2008, the Mesa de Organizacions con Trabajo en VIH/SIDA and the Red Colombiana de Personas Viviendo con VIH o con SIDA requested an open license on Kaletra. The local Colombian generics industry has the capacity to manufacture Kaletra at much lower costs AND Colombia has an agreement with the Clinton Foundation through which it could get a generic version of Kaletra for approximately $600 per patient per year.(12) Abbott did not respond.



About AHF



AIDS Healthcare Foundation (AHF) is the nation's largest non-profit HIV/AIDS healthcare provider. AHF currently provides medical care and/or services to more than 100,000 individuals in 21 countries worldwide in the US, Africa, Latin America/Caribbean and Asia. Additional information is available at www.aidshealth.org



(1) United Nations Development Program ( www.undp.org )


(2) Resumen de Situacion de la Epidemia por VIH/SIDA en Colombia. (Dec 2007) Ministerio de Proteccion Social, Colombia.


(3) UNAIDS http://www.unaids.org/en/CountryResponses/Countries/default.asp



(4) World Health Organization (April 2008). Universal Access Report.



(5) 2008 UNGASS Report, Colombia.



(6) http://www.abbott.com/global/url/content/en_US/40.5.10:10/general_content/General_Content_00327.htm



(7) Garavito, L, Gomez, F. (2006) Analisis regulatorio del mercardo institucional de medicamentos antiretrovirales en Colombia.



(8) Personal Communication with Abbott Laboratories in Colombia.



(9) Local price survey.



(10) AHF can provide 1st hand accounts on request.



(11) Garavito, L, Gomez, F. (2006) Analisis regulatorio del mercardo institucional de medicamentos antiretrovirales en Colombia.



(12) Clinton HIV/AIDS Initiative. www.clintonfoundation.org


SOURCE AIDS Healthcare Foundation

------------------------------------------------------------------------------------------------

[THE COLOMBIAN GOVERNMENT ACTIONS VIOLATE THE WTO TRIPS AGREEMENT IN SEVERAL IMPORTANT WAYS].



ILA COMMITTEE ON LEGAL ISSUES OF THE OUTER CONTINENTAL SHELF
  • The WTO TRIPS flexibilities” contained within TRIPS Article 31, the Doha Declaration on TRIPS and Public Health, the TRIPS Council Decision on Paragraph 6 and the proposed Article 31bis Waiver to the TRIPS Agreement concerning same emphasize that intellectual property are property rights, first and foremost, within the meaning of TRIPS Preamble Paragraph 4, and are deserving of adequate protection against governmental expropriation.

    ILA COMMITTEE ON LEGAL ISSUES OF THE OUTER CONTINENTAL SHELF
  • Since property rights are natural, individual-based human rights, within the meaning of the 1948 Declaration, the 1948 American Declaration on the Rights and Duties of Man, the 1976 International Covenant on Economic, Social and Cultural Rights, and ultimately, the United States Constitution (1787) and its accompanying Bill of Rights (1791), then governments must pay heed to the strict substantive and procedural conditions imposed on unauthorized governmental ‘takings’ of private IP rights set forth within WTO TRIPS Article 31(a), (d), (h), (i), (j) and (k); 44.2; and 62.44.

    ILA COMMITTEE ON LEGAL ISSUES OF THE OUTER CONTINENTAL SHELF
  • While the TRIPS Agreement may have grandfathered the highly disputed Paris Convention grounds for issuing compulsory licenses (incorporated by reference within TRIPS Article 2 and the Preamble to TRIPS Article 31) (‘the broad mouth of the funnel’), these bases remain tightly circumscribed by the substantive and procedural conditions imposed by the subsections to TRIPS Article 31. These provisions were arguably intended to ensure protection of patentees’ affirmative right to substantive and procedural due process of law against wanton governmental seizures of exclusive private property (human) rights within the meaning of the Fifth Amendment of the U.S. Bill of Rights and other U.S. constitutional provisions (‘the narrow neck of the funnel’).
  • ILA COMMITTEE ON LEGAL ISSUES OF THE OUTER CONTINENTAL SHELFILA COMMITTEE ON LEGAL ISSUES OF THE OUTER CONTINENTAL SHELFILA COMMITTEE ON LEGAL ISSUES OF THE OUTER CONTINENTAL SHELF



  • This means that when a government or an intergovernmental organization such as the WHO, etc. wishes to ‘take’ patented private medicine or medical technology products for a ‘public use’ (i.e., on the basis of an identified and declared ‘public interest’), that government or intergovernmental organization must pay itself, or cause a selected third party licensee to pay, full, complete and adequate fair market value compensation for such patents. After all, this is consistent with established U.S. Supreme Court jurisprudence and with the understanding of the parties to the WTO TRIPS and WIPO Agreements. And, fair market value means ‘arms-length’ pricing agreed to between a willing buyer and a willing seller; not some unilaterally predetermined price deemed to be ‘fair’ by a national or regional government or intergovernmental body.
ILA COMMITTEE ON LEGAL ISSUES OF THE OUTER CONTINENTAL SHELF

[See: ITSSD Comments on ‘Desk Review of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property from a Right to Development Perspective’, accessible on the ITSSD website at: http://www.itssd.org/ITSSD%20comments%20on%20Desk%20Review%20of%20IGWG%20CIPIH%20from%20a%20Rt%20to%20Development%20Perspective%20_2_.pdf ].


[See: Desk Review of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property from a Right to Development Perspective, High-Level Task Force on the implementation of the Right to Development, United Nations High Commissioner on Human Rights, A/HRC/12/WG.2/TF/CRP.5, at: http://www2.ohchr.org/english/issues/development/right/docs/A-HRC-12-WG2-TF-CRP5.doc; http://www2.ohchr.org/english/issues/development/right/high_level_task_force_Right_to_Development_5th.htm ].


[See: ITSSD Comments Concerning (Document SCP/13/3) Exclusions from Patentable Subject Matter and Exceptions and Limitations to the Rights , World Intellectual Property Organization (WIPO) Standing Committee on the Law of Patents (March 2009) at:ILA COMMITTEE ON LEGAL ISSUES OF THE OUTER CONTINENTAL SHELF http://www.itssd.org/ITSSD%20Comments%20Concerning%20Document%20SCP%2013-3%20-%20Patent%20Exclusions,%20Exceptions%20&%20Limitations%20-%203-27-09%20-II.doc].

Friday, February 13, 2009

What Comes Around, Goes Around - Russian Bear Bitten by Chinese Dragon's IP & Industrial Piracy!

Russia Admits China Illegally Copied Its Fighter

By Wendell Minnick

Defense News

February 13, 2009

BANGALORE, India - After years of denial, a Russian defense official conceded that China had produced its own "fake" version of the Su-27SK fighter jet in violation of intellectual property agreements.

"We are in discussions with China on this issue," said Mikhail Pogosyan, first vice president on program coordination, Russian Aircraft Corp., during a press conference here at the Aero India trade show.

In 1995, China secured a production license to build 200 Su-27SKs, dubbed J-11A, for $2.5 billion for the Shenyang Aircraft Corp. The deal required the aircraft to be outfitted with Russian avionics, radars and engines. Russia cancelled the arrangement at 95 aircraft in 2006 after it discovered that China was developing an indigenous version, J-11B, with Chinese avionics and systems.


China produced six J-11B fighters for testing, but despite efforts to produce a suitable replacement for the Russian engine, the new fighter was outfitted with the same AL-31F, said Andrei Chang, a China military specialist at the Kanwa Defense Center. One J-11A was outfitted with the indigenously-built WS10A Tai Hang turbofan engine, but the J-11Bs are still using Russian AL-31Fs due to technical difficulties, Chang said.


Pogosyan and Russian Defense Minister Anatoly Serdyukov traveled to Beijing in December to attend the 13th session of a Chinese-Russian joint commission on military and technical cooperation and apply pressure to Chinese officials. Ultimately, China agreed to protect intellectual property rights and stop illegally copying Russian military equipment.


"I think this was a big step to make this issue more transparent and more precise in our future discussions," said Pogosyan, who also serves as the general director of Sukhoi.


Russia fears that China would mass-produce cheaper export versions of the Su-27 for the international market, and China feared that Russia would cancel future orders for advanced arms, such as the Su-33 combat jet for China's aircraft carrier program, Chang said. Chinese violations of the end-user agreement would be particularly upsetting to Russia's long-time strategic partner India, if Pakistan buys the Chinese-built Su-27 version.


However, Pogosyan downplayed the quality of the Chinese effort, saying a copy of a copy would not be a good aircraft.


"If we speak about the copy of the airplanes, I think that in this case, the original will always be better than a slightly modified copy," he said. "The original made by the designer who developed the product is always better, and it is a better start for a new program with the original designer and developer than making a fake copy."


He said buying copies makes it difficult to overcome problems occurring during the lifetime of the aircraft, while the original developer knows from experience how to deal with these issues.
Chang does not believe China will honor the intellectual property agreement, or any agreement with Russia, and will continue to develop the J-11B as a totally indigenous aircraft. However, China will move cautiously until it secures deals for the Su-33 carrier-based fighter. China is beginning to build its first aircraft carrier and needs Russian technology and experience, Chang said.
------------------------------------------------------------------------------------------------

Russian 5th gen Su-35: Spinoff of Su-27 Made in China as J-11


Posted on July 9, 2008 by Moin Ansari

Rupee News

Noticias de Rupia Nouvelles de Roupie Rupiennachrichten новости рупии 卢比新闻 Roepienieuws Rupi Nyheter ルピーニュース Notizie di Rupia PAKISTAN LEDGER پاکستاني کھاتا Moin Ansari معین آنصآرّی


Russia has supplied China with weapons worth a total of more than $25 billion for the past 15 years. Aircraft, ships and air defenses account for the bulk of this sum.

China’s armed forces have more than 280 Su-27SK, Su-27UBK, Su-30MKK and Su-30MK2 fighters.

Several years ago, China signed a contract authorizing it to assemble 200 Su-27SK fighters. After building 105 planes, China unilaterally suspended the deal. Many believe that China is manufacturing a fighter that is in effect a replica of the Russian Sukhoi SU-27. Russian arms “Made in China”. China used the opportunity to develop its own domestic manufacturing and now has local capacity to build the next generation of aircraft. Why did Pakistan buy fewer F-16s? Hint:-Indigenous Flanker!



India has imported 60 of the Su with no indigenous capability and continues import planes to the tune of $126 Billion.Chinese J-11s for Pakistan?

What about the SU-35? The original Su-35 was a derivative of the Su-27 and essentially a ground-based variant of the Su-33. While the official Russian Air Force designation for the aircraft remained the Su-27M, Sukhoi rechristened the model as the Su-35 in the hopes of attracting foreign customers. The Brazilians wanted to produce it but in the end opted for the Mirage IIIs.


The Brazilian decision appeared to have ended the Su-35 program once and for all since Sukhoi had little success finding other customers. Hopes were briefly revived in May 2006 when Venezuela announced interest in the Su-35, but the nation instead chose a variant of the Su-30. The move is largely politically-motivated given recent tensions between Venezuela and the United States over America’s ban on providing support for the Venezuelan F-16 fleet. the Su-35 was revived at least in name in 2007 when Sukhoi announced the aircraft had entered production for the Russian Air Force. This incarnation is also a derivative of the Su-27.

A derivative of the Su-27 ‘Flanker’, the Su-37 is a super-maneuverable thrust vectoring fighter. Designed from an Su-35 prototype, the Su-37 test aircraft (designated T10M-11) made its maiden flight in April 1996 from the Zhukovsky flight testing center near Moscow. The Su-37 is first Russian aircraft to feature thrust vectoring control comparable to the F-22 Raptor.

MOSCOW, February 21 [2008??] (RIA Novosti) - China has built a domestic copy of the famed Su-27 Flanker fighter and may compete with Russia on third-party markets if it sets up the full-scale production of the plane, a Russian daily said on Thursday.


China has acquired 76 Su-27SK fighters from Russia since 1992, and bought a license for production of another 200 planes in 1995, in a deal worth $2.5 billion.

“Since 1996, the domestic version of the Su-27 aircraft, dubbed J-11, has been produced at the Shenyang Aircraft Corporation (SAC) with the use of Russian components,” the Vedomosti newspaper said.

The licensed production of the Su-27 has given China its most capable fighter aircraft while also providing a vehicle for its industry to gain knowledge of third-generation fighter manufacturing, Vedomosti said.

...Soon the Su-37 was developed on the basis of the Su-35. Often confused with the experimental C.37/Su-47 aircraft, the Su-37 was equipped with thrust-vectoring engines, which was the main difference between this model and the Su-35. The No. 711 Su-37 prototype impressed specialists greatly by its outstanding maneuverability, but remained one-of-a-kind.

Monday, January 26, 2009

Brazil's 'Public Interest' IP Opportunism Knows No Limits - Third Country Transit Points Now Being Used

http://www.reuters.com/article/marketsNews/idUSN2327254420090123

Brazil to Object to Dutch Seizure of Generic Drug


Reuters


By Pedro Fonseca and Reese Ewing


Jan 23, 2009


RIO DE JANEIRO, Jan 23 (Reuters) - Brazil said it would file a complaint at the World Trade Organization over the seizure by Dutch authorities of a shipment of a generic high blood pressure drug made in India.


Local foreign and health ministries said a company claiming to have intellectual property rights to the arterial hypertension drug losartan in the Netherlands requested customs authorities seize a shipment of a generic version of the drug in transit from India to Brazil, two countries where the patent is not protected.


The Brazilian government can withhold intellectual property rights for a drug if it considers it "in the public interest." Its health-care system provides free drug treatment for certain conditions such as AIDS and high blood pressure.


"The Brazilian government feels that the decision by the Dutch authorities to detain the basic material critical for the public health of a developing country ... a serious step backward on the question of universal access to drugs," said the note released by the Brazilian ministries late Thursday.


[SINCE WHEN IS BRAZIL A DEVELOPING COUNTRY??? IT IS AN AGRICULTURAL & ENERGY SUPERPOWER!! AT THE VERY LEAST, IT IS AN EMERGING ECONOMY!! SORRY GUYS. THIS ARGUMENT NO LONGER WORKS!! IT'S TIME TO INVEST IN PUBLIC EDUCATION!]


The statement also said the government would take its complaint to the executive council of the World Trade Organization in Geneva.


High blood pressure is one of the leading causes of death among Brazilians.


[SO MUCH FOR PUBLIC EMERGENCY OR EXIGENT CIRCUMSTANCES OR ANTITRUST ACTIVITY AS AN EXCUSE FOR A 'TAKING'. NOW ALL THAT IS NECESSARY IS THAT THE BRAZILIANS WANT WHAT THE FOREIGN PATENT HOLDERS HAVE!! THIS IS WHAT THEY CALL 'PUBLIC INTEREST'!!]


The cargo of generic losartan that was seized in Rotterdam was sent back to India, where it was manufactured by Dr. Reddy's, the ministries' note said. The drug was being imported by Brazil's EMS.



[NOW, WHY WOULD THE BRAZILIAN SHIPPER USE ROTTERDAM AS A THIRD COUNTRY TRANSIT POINT BETWEEN INDIA AND BRAZIL??? AND WHY WOULD DR. REDDY'S, WHICH IS ALL-TOO FAMILIAR WITH THE LAW OF PATENTS, WANT TO DO THIS??? ARE THERE ANY TARIFF BENEFITS OR FINANCIAL PAYOFFS?? WHY WOULD THE DUTCH GOVERNMENT INTERVENE ON BEHALF OF FRENCH AND AMERICAN PATENT HOLDERS?? DOES IT HAVE A LEGAL DUTY TO DO SO?? ARE THESE DRUGS PATENTED ALSO IN THE NETHERLANDS?? HOW DID THE PATENT HOLDERS GET WIND OF THE SHIPMENT??]



Losartan is the generic name for the drug Cozaar that was co-developed by Merck & Co and DuPont Co.


------------------------------------------------------------------------------------------------


Brazil Protests Seizure of Dr. Reddy’s Drugs in the Netherlands


By Joshua Goodman


Jan. 21 (Bloomberg)


Brazil protested the seizure in the Netherlands of shipments from Dr. Reddy’s Laboratories Ltd., India’s second-biggest drugmaker.


Customs authorities in Rotterdam seized shipments of the generic drug Losartan, used to treat high blood pressure, while in transit to Brazil, the South American nation’s foreign ministry said in a statement.


Authorities were acting on the request of an unnamed [???] company that allegedly has patent rights over the drug in the Netherlands, the foreign ministry said. Losartan can be imported freely in Brazil.


“The decision by Dutch authorities to seize a strategic supply for the public health system of a developing country, exported according to international norms, signals a grave step backward in the universal access to medicines,” the ministry said in the statement.


[BRAZIL IS NOT A DEVELOPING COUNTRY!!]


Officials at the Netherlands embassy in Brazil weren’t immediately available to comment after normal business hours.


The Brazil foreign ministry said the seizure “raises doubts about the commitment of European countries to help people in developing countries gain access to medicines.”


[BRAZIL IS NOT A DEVELOPING COUNTRY!!]


Brazil plans to complain to the World Health Organization in Geneva and possibly to the World Trade Organization.

The drug shipment has been returned to India, the foreign ministry said.